Androgen-induced vasorelaxation: a potential vascular protective effect

M Perusquía1

  • 1Department of Cell Biology and Physiology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico. perusqui@servidor.unam.mx

Insights

Androgens, hormones primarily associated with males, may offer cardiovascular benefits by widening blood vessels. Further research is needed to fully understand their protective mechanisms and clinical implications in heart health.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Molecular Biology

Background:

  • Cardiovascular disease (CVD) exhibits higher morbidity and mortality rates in men compared to women.
  • Historically, research has concentrated on androgens' role in cardiovascular pathology.
  • The precise clinical significance and molecular actions of androgens in the cardiovascular system remain incompletely understood.

Purpose of the Study:

  • To review existing evidence on the vasodilatory effects of androgens.
  • To explore the underlying molecular mechanisms responsible for androgen-mediated vasodilation.
  • To examine the structure-function relationship of androgens concerning their cardiovascular effects.

Main Methods:

  • Literature review of experimental and clinical studies.
  • Analysis of research focusing on androgen action in cardiovascular pathways.
  • Examination of structure-activity relationships relevant to androgen's cardiovascular impact.

Main Results:

  • Emerging evidence suggests androgens may exert beneficial effects on the cardiovascular system.
  • Androgens have demonstrated a vasodilating effect, contributing to improved blood flow.
  • Specific molecular pathways and structure-function correlations are being elucidated.

Conclusions:

  • Androgens possess vasodilating properties with potential protective roles in cardiovascular health.
  • Understanding the molecular mechanisms and structure-function relationships is crucial for clinical applications.
  • Further investigation is warranted to establish the full therapeutic potential of androgens in managing cardiovascular diseases.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.